MAM
FSTX

Morse Asset Management’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History

Morse Asset Management’s Portfolio FSTX Stock Details FSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-10,734
Closed -$148K – 144
2019
Q3 		$148K Buy
10,734
+7,725
+257% +$127K 0.06% 121
2019
Q2 		$44K Sell
3,009
-34,285
-92% -$918K 0.01% 131
2019
Q1 		$1.56M Sell
37,294
-4,881
-12% -$206K 0.47% 60
2018
Q4 		$1.75M Sell
42,175
-5,338
-11% -$240K 0.62% 47
2018
Q3 		$2.29M Buy
47,513
+3,138
+7% +$157K 0.6% 51
2018
Q2 		$2.1M Buy
44,375
+2,931
+7% +$163K 0.58% 50
2018
Q1 		$2.49M Buy
41,444
+4,725
+13% +$249K 0.69% 47
2017
Q4 		$1.82M Buy
36,719
+5,719
+18% +$340K 0.51% 58
2017
Q3 		$2M Buy
31,000
+15,075
+95% +$863K 0.6% 59
2017
Q2 		$862K Buy
15,925
+9,725
+157% +$450K 0.28% 79
2017
Q1 		$223K Buy
+6,200
New +$213K 0.08% 125

Other funds holding FSTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TA
Tiedemann Advisors New York $2.33B AUM 15.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
HP
Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morse Asset Management's FSTX Position: Q4 2019 in Review

Morse Asset Management sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q4 2019, closing a stake of 10,734 shares — an estimated $148K sold.

Morse Asset Management first reported a position in FSTX in Q1 2017 and held it in 11 quarters. The position peaked at $2.49M in Q1 2018. 31 funds tracked by Wall St. Rank hold FSTX as of Q4 2019.

  • Morse Asset Management reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Morse Asset Management sold 10,734 F-star Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $148K.
  • Morse Asset Management first reported a position in F-star Therapeutics, Inc. Common Stock in Q1 2017 and held it in 11 quarters.
  • Morse Asset Management's F-star Therapeutics, Inc. Common Stock position peaked at $2.49M in Q1 2018.
  • 31 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q4 2019.

Based on Morse Asset Management's 13F filing for Q4 2019, filed 31 Jan 2020.